PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone
NCT00291005
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostatic Neoplasms
Interventions
DRUG:
ARD6562, Docetaxel
Sponsor
Sanofi